| 翻訳と辞書 |
ZMapp
ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Dr. Gary Kobinger, the recently-departed branch chief of the NML and is undergoing further development under license by Mapp Biopharmaceutical. Zmapp was first tested in humans during the 2014 West Africa Ebola virus outbreak, but has not been subjected to a randomized controlled trial to determine whether it works, and whether it is safe enough to allow on the market.
==Medical use==
ZMapp is under development as a treatment for Ebola virus disease.〔 It was first used experimentally to treat some people with Ebola virus disease during the 2014 West African Ebola outbreak, but as of August 2014 it had not yet been tested in a clinical trial to support widespread usage in humans; it is not known whether it is effective to treat the disease, nor if it is safe.〔(【引用サイトリンク】title=WHO Experts Give Nod to Using Untested Ebola Drugs )〕〔(【引用サイトリンク】title=WHO – Ethical considerations for use of unregistered interventions for Ebola virus disease )〕〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「ZMapp」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|